Eli Lilly and Company (NYSE:LLY) Shares Bought by TKG Advisors LLC

TKG Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 5.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 7,359 shares of the company’s stock after acquiring an additional 413 shares during the period. Eli Lilly and comprises about 2.1% of TKG Advisors LLC’s holdings, making the stock its 17th biggest holding. TKG Advisors LLC’s holdings in Eli Lilly and were worth $2,386,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. IFM Investors Pty Ltd raised its position in shares of Eli Lilly and by 7.1% in the second quarter. IFM Investors Pty Ltd now owns 137,974 shares of the company’s stock valued at $44,735,000 after buying an additional 9,201 shares during the last quarter. Marcum Wealth LLC grew its holdings in shares of Eli Lilly and by 9.1% in the second quarter. Marcum Wealth LLC now owns 4,101 shares of the company’s stock valued at $1,330,000 after purchasing an additional 343 shares during the period. Orion Portfolio Solutions LLC grew its holdings in shares of Eli Lilly and by 3.5% in the second quarter. Orion Portfolio Solutions LLC now owns 5,570 shares of the company’s stock valued at $1,806,000 after purchasing an additional 186 shares during the period. Steigerwald Gordon & Koch Inc. grew its holdings in shares of Eli Lilly and by 19.0% in the second quarter. Steigerwald Gordon & Koch Inc. now owns 3,769 shares of the company’s stock valued at $1,222,000 after purchasing an additional 603 shares during the period. Finally, Adviser Investments LLC grew its holdings in shares of Eli Lilly and by 12.2% in the second quarter. Adviser Investments LLC now owns 1,465 shares of the company’s stock valued at $475,000 after purchasing an additional 159 shares during the period. 82.45% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction that occurred on Friday, June 24th. The shares were sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now owns 104,203,810 shares of the company’s stock, valued at $33,794,337,621.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction on Friday, June 24th. The shares were sold at an average price of $324.31, for a total value of $69,726,650.00. Following the transaction, the insider now directly owns 104,203,810 shares of the company’s stock, valued at approximately $33,794,337,621.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 543,125 shares of company stock valued at $178,307,801. 0.12% of the stock is owned by corporate insiders.

Eli Lilly and Stock Up 4.9 %

NYSE:LLY traded up $14.39 during mid-day trading on Thursday, hitting $310.87. The stock had a trading volume of 5,873,996 shares, compared to its average volume of 2,852,736. The stock has a 50-day simple moving average of $314.65 and a two-hundred day simple moving average of $304.11. The company has a market capitalization of $295.38 billion, a PE ratio of 47.29, a PEG ratio of 1.95 and a beta of 0.38. Eli Lilly and Company has a twelve month low of $220.20 and a twelve month high of $335.33. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $1.87 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current year.

Eli Lilly and Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a dividend of $0.98 per share. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a yield of 1.26%. Eli Lilly and’s payout ratio is currently 62.52%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on LLY shares. Morgan Stanley upped their price objective on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a report on Wednesday, September 7th. Citigroup upped their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. BMO Capital Markets increased their target price on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 6th. Finally, UBS Group raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and increased their target price for the stock from $335.00 to $363.00 in a research note on Thursday. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Eli Lilly and has an average rating of “Moderate Buy” and an average target price of $332.19.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.